XTL BiopharmaceuticalsXTLB -7.99%24 Current Ratio is 0.70 as of Jun. 2025, which is 97% below its 10-year median of 20.53. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 88.42% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. XTL Biopharmaceuticals's current ratio for the quarter that ended in Jun. 2025 was 0.70.
XTL Biopharmaceuticals has a current ratio of 0.70. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If XTL Biopharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for XTL Biopharmaceuticals's Current Ratio or its related term are showing as below:
XTLB'
s Current Ratio Range Over the Past 10 Years
Min: 0.61 Med: 20.53 Max: 45.12
Current: 0.7
During the past 13 years, XTL Biopharmaceuticals's highest Current Ratio was 45.12. The lowest was 0.61. And the median was 20.53.
XTLB's Current Ratio is ranked worse than 88.42% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs XTLB: 0.70
XTL Biopharmaceuticals (NAS:XTLB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
XTL Biopharmaceuticals Current Ratio Related Terms
XTL Biopharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTLB vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, XTL Biopharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals (XTLB) has a Current Ratio of 0.70 as of Jun. 2025. This is 97% below median its historical median of 20.53. Over the past decade, XTL Biopharmaceuticals' Current Ratio has ranged from 0.61 to 45.12. According to the industry distribution chart, XTL Biopharmaceuticals ranks #1252 out of 1416 companies in the Biotechnology industry, placing it in the top 88.4%.
Is XTL Biopharmaceuticals' Current Ratio too high?
XTL Biopharmaceuticals' current Current Ratio of 0.70 is 97% below median its 10-year median of 20.53. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 45.12. The Biotechnology industry median Current Ratio is 3.89. XTL Biopharmaceuticals' value of 0.70 is 82% below this industry median. Based on the distribution chart, XTL Biopharmaceuticals ranks #1252 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #1252 out of 1416 companies for Current Ratio. This places XTL Biopharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. XTL Biopharmaceuticals' value of 0.70 is 82% below this benchmark. Historically, XTL Biopharmaceuticals' own Current Ratio has ranged from 0.61 to 45.12 over the past decade. While the company's 10-year median is 20.53 vs. the industry median of 3.89, XTL Biopharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XTL Biopharmaceuticals's current Current Ratio of 0.70 is 82% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current Current Ratio is 0.70, which is 97% below median its own 10-year median of 20.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Current Ratio of 0.70. The current Current Ratio is 0.70, which is 97% below median its 10-year median of 20.53 and 82% below the Biotechnology industry median of 3.89. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Current Ratio is 0.70 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score
Get the complete analysis for XTLB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
